title: Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
abstract: BACKGROUND
  The Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) is a relatively new type of coronary stent designed to provide temporary vessel scaffolding following percutaneous coronary intervention. International use of the device has grown despite a relative paucity of clinical data regarding the performance of the device and the optimal strategy for its use. We report 12-month clinical data on the Absorb BVS from a real-world registry in order to contribute to the overall understanding of the BVS device.
  
  
  RESULTS
  Absorb BVS implantation was attempted in 152 lesions in 100 patients at two Sydney hospitals, as part of the prospective ESHC-BVS registry. Patients selected harbored a range of complex lesions as encountered in real-world practice. Type-C lesions made up 37% of all lesions treated, with 64% of these being long lesions (>20 mm). Device success was achieved in 98.8% of cases. Predilation was performed in all scaffolds and postdilation was performed in 95% of scaffolds to a mean of 19.6 ± 4.6 atm. Twelve-month follow-up data were available for 99% of patients. At 12 months, the cumulative incidence of target-lesion revascularization was 4%, while the incidence of myocardial infarction was 2% and the incidence of scaffold thrombosis was 1%. There were no deaths in the follow-up period.
  
  
  CONCLUSIONS
  In a cohort including complex lesions encountered in real-world practice, the Absorb BVS was associated with low rates of target-lesion revascularization, myocardial infarction, and scaffold thrombosis at 12 months when used with a strategy of meticulous lesion preparation, routine postdilation, and 12 months of dual-antiplatelet therapy.
authors.forename: Daniel
authors.initials: D
authors.lastname: Robaei
authors.forename: Liam
authors.initials: L
authors.lastname: Back
authors.forename: Sze-Yuan
authors.initials: SY
authors.lastname: Ooi
authors.forename: Mark
authors.initials: M
authors.lastname: Pitney
authors.affiliation: Eastern Heart Clinic, Prince of Wales Hospital, Level 3 Campus Centre Building, Barker St, Randwick NSW 2031, Australia. nigel.jepson@ehc.com.au.
authors.forename: Nigel
authors.initials: N
authors.lastname: Jepson
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects / Q000706:statistics & numerical data; D000368:Aged; D001315:Australia / Q000453:epidemiology; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000453:epidemiology / Q000601:surgery; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology / Q000209:etiology; D011474:Prosthesis Design; D012042:Registries; D054457:Tissue Scaffolds / Q000706:statistics & numerical data